About

Dr. Christine Boers-Doets, PhD

Oncology nurse. Doctoral researcher. Founder of the Dutch centre of expertise for the side effects of cancer medicines.

Biography

From the bedside to international guidelines

Portrait of Dr. Christine Boers-Doets

I began my career as an oncology nurse, caring for people going through cancer treatment. Again and again I saw the same thing: powerful medicines undermined not by the cancer, but by side effects that left patients unable to continue.

That question — how do we keep people on treatment? — became my life’s work. I moved from the bedside into research, specialising in the dermatologic (skin) and oral, mucosal toxicities of targeted therapy, immunotherapy and endocrine treatment.

In 2019 I defended my PhD at Leiden University Medical Center with a dissertation titled “Towards a patient-driven approach to adverse events of targeted agents in oncology.” Along the way I co-developed the FACT-EGFRI-18 quality-of-life instrument and contributed to international MASCC and ESO–ESMO consensus guidelines.

Today I lead the CancerMed Side Effects Institute and NEBK — the Dutch Centre of Expertise for Side Effects of Cancer Medicines — teaching clinicians, guiding patients, and helping care organisations and industry raise the standard of adverse-event care.

Active member of MASCC, the Multinational Association of Supportive Care in Cancer.

Career milestones

Two decades building the field

  • 2012Founded the IMPAQTT Foundation to advance patient-centred adverse-event care.
  • 2013Established CancerMed to bring side-effect expertise to clinicians and industry.
  • 2014Published The TARGET System Book, setting out her six-step method.
  • 2019Awarded her PhD at Leiden University Medical Center; became Managing Director of CancerMed B.V.
  • TodayLeads NEBK, the Dutch Centre of Expertise for Side Effects of Cancer Medicines.

Areas of expertise

What I specialise in

Targeted-therapy adverse eventsImmunotherapy side effectsDermatologic (skin) toxicitiesOral & mucosal toxicitiesEGFR-inhibitor skin reactionsPatient-reported outcomesSupportive & home-based cancer careClinician education & curricula
“Teach people that they can choose to take control of side effects.”

That belief runs through everything I do — because when side effects are controlled, cancer medicines finally get the chance to do their job.